S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
All the trading advice you’ve ever received boils down to this (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
All the trading advice you’ve ever received boils down to this (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

POINT Biopharma Global (PNT) Stock Forecast & Price Target

$13.81
+0.09 (+0.66%)
(As of 12/6/2023 ET)
Compare
Today's Range
$13.62
$13.95
50-Day Range
$6.67
$13.81
52-Week Range
$6.39
$14.00
Volume
1.36 million shs
Average Volume
1.20 million shs
Market Capitalization
$1.47 billion
P/E Ratio
15.34
Dividend Yield
N/A
Price Target
$12.88

POINT Biopharma Global Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$12.88
-6.77% Downside
High Forecast$14.00
Average Forecast$12.88
Low Forecast$12.50
TypeCurrent Forecast
12/7/22 to 12/7/23
1 Month Ago
11/7/22 to 11/7/23
3 Months Ago
9/8/22 to 9/8/23
1 Year Ago
12/7/21 to 12/7/22
Consensus Rating
Hold
Hold
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
6 Buy rating(s)
8 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$12.88$13.42$16.00$23.00
Predicted Upside-6.77% Downside24.19% Upside99.47% Upside223.61% Upside
Get POINT Biopharma Global Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PNT and its competitors with MarketBeat's FREE daily newsletter.


PNT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PNT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

POINT Biopharma Global Stock vs. The Competition

TypePOINT Biopharma GlobalMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.67
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside-6.77% Downside670.39% Upside2,089.54% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Neutral$12.50-2.19%
10/6/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
F. Khurshid
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
10/5/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$13.00 ➝ $12.50+0.81%
10/4/2023Jonestrading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
10/4/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
10/3/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hsieh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
10/3/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
10/3/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$13.00 ➝ $12.50+0.89%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:16 AM ET.












PNT Price Target - Frequently Asked Questions

What is POINT Biopharma Global's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for POINT Biopharma Global stock is Hold based on the current 9 hold ratings for PNT. The average twelve-month price prediction for POINT Biopharma Global is $12.88 with a high price target of $14.00 and a low price target of $12.50. Learn more on PNT's analyst rating history.

Do Wall Street analysts like POINT Biopharma Global more than its competitors?

Analysts like POINT Biopharma Global less than other Medical companies. The consensus rating for POINT Biopharma Global is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how PNT compares to other companies.

Is POINT Biopharma Global being downgraded by Wall Street analysts?

Over the previous 90 days, POINT Biopharma Global's stock had 7 downgrades by analysts.

Does POINT Biopharma Global's stock price have much upside?

According to analysts, POINT Biopharma Global's stock has a predicted upside of 6.78% based on their 12-month stock forecasts.

What analysts cover POINT Biopharma Global?

Stock Ratings Reports and Tools

This page (NASDAQ:PNT) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -